Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients

American Journal of Psychiatry

Volumn 155, Issue 3, 1998, Pages 337-343

  Bartlett, Elsa J ^b   Brodie, Jonathan D ^a   Simkowitz, Philip ^b   Schlösser, Ralf ^b   Dewey, Stephen L ^b   Lindenmayer, Jean Pierre ^b   Rusinek, Henry ^b   Wolkin, Adam ^b   Cancro, Robert ^b   Schiffer, Wynne ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; PROLACTIN;

ARTICLE; BRAIN METABOLISM; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CORPUS STRIATUM; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG RESPONSE; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; NEOCORTEX; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BLOCKING; SCHIZOPHRENIA; TEMPORAL CORTEX; THALAMUS; TREATMENT OUTCOME;

EID: 0031940782     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.3.337     Document Type: Article

References (30)

1. Seeman P:Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1:133-152
2. Miller R:The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness. Psychopharmacology (Berl) 1987; 92:405-415
3. Nordstrom A-L, Farde L, Halldin C:Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992; 106: 433-438
4. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y, Cooper TB, Brodie JD:Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905-908
5. Coppens H, Slooff C, Paans A, Wiegman T, Vaalburg W, Korf J:High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy resistant schizophrenic patients. Biol Psychiatry 1991; 29:629-634
6. Harriett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Wolf AP, Fowler JS, Volkow ND, Smith G, Wolkin A, Cancro R:Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry 1994; 151: 681-686
7. Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Volkow ND, Wolf AP, Smith G, Wolkin A, Cancro R:Time-dependent effects of a haloperidol challenge on energy metabolism in the normal human brain. Psychiatry Res 1996; 60:91-99
8. Overall JE, Gorham DR:Introduction: the Brief Psychiatric Rating Scale: recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 24:97-99
9. Pelizzari CA, Chen GTY, Speibring DR, Weichselbaum RR, Chen C:Accurate three-dimensional registration of CT, PET and/or MR images of the brain. J Comput Assist Tomogr 1989; 13:20-26
10. Rusinek H, Tsui W-H, Levy AV, Noz ME, deLeon M:Principal axes and surface fitting methods for three-dimensional image registration. J Nucl Med 1993; 34:2019-2024
11. Wilkinson L:SYSTAT: The System for Statistics. Evanston, Ill, Systat, 1990
12. Volkow ND, Levy A, Brodie JD, Wolf AP, Cancro R, Van Gelder P, Henn F:Low cerebellar metabolism in medicated patients with chronic schizophrenia. Am J Psychiatry 1992; 149:686-688
13. Andreasen NC, O'Leary DS, Cizadlo T, Arndt S, Rezai K, Boles Ponto LL, Watkins GL, Hichwa RD:Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci USA 1996; 93:9985-9990
14. Phelps ME, Mazziotta JC, Kuhl DE, Nuwer M, Packwood J, Metter J, Engel J Jr:Tomographic mapping of human cerebral metabolism visual stimulation and deprivation. Neurology 1981; 31:517-529
15. Moore KE:Hypothalamic dopaminergic neuronal systems, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven Press, 1987, pp 127-139
16. Alexander GE, Crutcher MD, DeLong MR:Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990; 85: 119-146
17. Siegel BV Jr, Buchsbaum MS, Bunney WE Jr, Gottschalk LA, Haier RJ, Lohr JB, Lottenberg S, Najafi A, Nuechterlein KH, Potkin SG, Wu JC:Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry 1993; 150:1325-1336
18. Swerdlow NR, Koob GF:Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of cortico-striato-pallido-thalamk function. Behavioral and Brain Sciences 1987; 10: 197-245
19. Brodie JD:Imaging for the clinical psychiatrist: facts, fantasies, and other musings. Am J Psychiatry 1996; 153:145-149
20. Farde L, Wiesel FA, Hall H, Halldin C, Stone-Elander S, Sedvall G:No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987; 44:671-672
21. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Soghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB:Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93:9235-9240
22. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D:Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94:2569-2574
23. Schloesser R, Simkowitz P, Bartlett EJ, Wolkin A, Smith GS, Dewey SL, Brodie JD:The study of neurotransmitter interactions using positron emission tomography and functional coupling. Clin Neuropharmacol 1996; 19:371-389
24. Wolkin A, Sanfilipo M, Duncan E, Angrist B, Wolf AP, Cooper TB, Brodie JD, Laska E, Rotrosen JP:Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 1996; 153:346-354
25. Friedhoff AJ, Simkowitz P:A new conception of the relationship between psychological coping mechanisms and biological stress buffering systems. Br J Psychiatry Suppl 1989; 4:61-66
26. Grace AA:Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroseience 1991; 41:1-24
27. Bilder RM:Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 1997; 42:255-264
28. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA:Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996; 153:41-49
29. Buchsbaum MS, Potkin SG, Marshall JF, Lottenberg S, Teng CY, Hen CW, Tafalla R, Reynolds C, Abel L, Plon L, Bunney WE Jr:Effects of clozapine and thiothixene tin glucose metabolic rate in schizophrenia. Neuropsychopharmacology 1992; 6:155-164
30. Buchsbaum MS, Potkin SG, Siegel BV Jr, Lohr J, Katz M, Gottschalk LA, Gulasekaram B, Marshall JF, Lottenberg S, Teng CY, Abel L, Plon L, Bunney WE Jr:Striatal metabolic rate and clinical response to neurolcptics in schizophrenia. Arch Gen Psychiatry 1992; 49:966-974